Page 734 - Read Online

Page 8 of 8 Palmieri et al. J Cancer Metastasis Treat 2020;6:55 I http://dx.doi.org/10.20517/2394-4722.2020.105

5. Palmieri M, Baldassarri M, Fava F, et al. Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients. Cancer
Med 2020;9:2052-61.
6. Braun S, Hepp F, Sommer HL, Pantel K. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for
immunotherapy of minimal residual disease. Int J Cancer 1999;84:1-5.
7. Ilié M, Hofman P. Pros: can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res 2016;5:420-3.
8. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl
J Med 2012;366:883-92.
9. Li BT, Stephens D, Chaft JE, et al. Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. Ann Transl
Med 2017;5:479.
10. Rossi G, Mu Z, Rademaker AW, et al. Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced
breast cancer. Clin Cancer Res 2018;24:560-8.
11. Li H, Zhu R, Wang L, et al. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 2010;88:150-5.
12. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell
2005;7:561-73.